We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...